治疗丙肝的第二代直接抗病毒药物的经济性系统评价

孟蕊; 芮明军; 马越; 金敏; 陈平钰

您当前的位置：

首页 >

文章列表页 >

治疗丙肝的第二代直接抗病毒药物的经济性系统评价

更新时间：2022-06-21

- 治疗丙肝的第二代直接抗病毒药物的经济性系统评价
- Systematic Review of the Economics of the Second-generation Direct-acting Antiviral Agents in the Treatment of Hepatitis C
- 中国药房 2020年31卷第23期
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  中图分类号：
- 纸质出版日期：2020，
扫描看全文
孟蕊, 芮明军, 马越, 等. 治疗丙肝的第二代直接抗病毒药物的经济性系统评价[J]. 中国药房, 2020,31(23).

MENG Rui, RUI Mingjun, MA Yue, et al. Systematic Review of the Economics of the Second-generation Direct-acting Antiviral Agents in the Treatment of Hepatitis C[J]. China Pharmacy, 2020,31(23).
孟蕊, 芮明军, 马越, 等. 治疗丙肝的第二代直接抗病毒药物的经济性系统评价[J]. 中国药房, 2020,31(23). DOI：

MENG Rui, RUI Mingjun, MA Yue, et al. Systematic Review of the Economics of the Second-generation Direct-acting Antiviral Agents in the Treatment of Hepatitis C[J]. China Pharmacy, 2020,31(23). DOI：

摘要

目的：系统评价治疗丙型病毒性肝炎（简称“丙肝”）的第二代直接抗病毒药物（DAAs）的药物经济学研究，为今后开展此类研究提供方法学建议，同时为医保目录调整及市场准入提供决策参考。方法：检索PubMed、Embase、TheCochraneLibrary、中国知网、万方数据库和维普数据库，收集治疗丙肝的第二代DAAs的经济学评价研究，检索时限为2015年1月－2020年1月。使用卫生经济学评价报告标准共识（CHEERS）清单评估纳入研究质量，提取资料汇总并进行定性分析。结果：共纳入14项研究，其标准符合率在79.2％～95.8％之间，属于较高质量研究。13项（92.9％）研究从付费方角度采用Markov模型及终生研究时限对比了不同治疗方案的经济性。与基于索磷布韦的第二代DAAs治疗方案比较时，所有研究结果显示，奥比帕利联合达塞布韦、艾尔巴韦/格拉瑞韦、格卡瑞韦/哌仑他韦这3种方案在目标国家的经济性更好；单因素敏感性分析显示，研究结果对于药品价格、药物病毒学应答（SVR）率和健康状态效用值3类参数较为敏感。结论：在治疗丙肝的第二代DAAs中，奥比帕利联合达塞布韦、艾尔巴韦/格拉瑞韦、格卡瑞韦/哌仑他韦这3种方案的药物经济性更好。建议今后的抗丙肝药物经济学研究采用动态模型和全社会的研究角度，对多种DAAs开展直接对比的高质量经济学研究；同时，在敏感性分析中考虑药品价格、药物SVR率和健康状态效用值等参数对基础分析结果稳健性的影响，以增加研究结果的可信度。

Abstract

OBJECTIVE：To systematically evaluate the pharmacoeconomic research of the second-generation direct-acting antiviral agents （DAAs）in the treatment of hepatitis C ，and to provide methodological suggestions for economic research ，and to provide decision-making reference for the adjustment of medical insurance catalogues and market access. METHODS ：Retrieved from PubMed ，EMbase，the Cochrane library ，CNKI，Wanfang database and VIP ，the pharmacoeconomic researches of the second-generation DAAs for hepatitis C were collected during Jan. 2015-Jan. 2020. The quality of included studies were evaluated with the checklist about Consolidated Health Economics Evaluation Reporting Standards （CHEERS），and the data were extracted and analyzed quantitatively. RESULTS ：A total of 14 studies were included ，and the standard coincidence rate ranged from 79.2％ to 95.8％；the overall quality was relatively high. Thirteen （92.9％）studies had compared the economics of different treatment schemes from the perspective of the payer by using the Markov model and the lifetime study time limit. Compared with the second-generation DAAs treatment schemes based on sofosbuvir ，all the research results showed that Ombitasvir combined with Dasabuvir（3D），EBR/GZR and GLE/PIB were more economical in the target countries ；single factor sensitivity analysis showed that the research results were more sensitive to the three parameters of drug price ，drug SVR rate and health status utility value. CONCLUSIONS：Among the second-generation DAAs for hepatitis C ，the three regimens of 3D，EBR/GZR and GLE/PIB are more economical. It is recommended that future research on the economics of medicines for hepatitis C adopted dynamic model and the research perspective of the whole society to carry out direct high-quality economic research on a variety of DAAs ；at the same time，considered the effects of drug price ，drug SVR rate and health status utility value on the robustness of basic analysis results in sensitivity analysis in order to increase the credibility of the research results.

关键词

丙型病毒性肝炎直接抗病毒药物模型方法学经济性评价系统评价

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

头孢哌酮舒巴坦致成人凝血功能异常危险因素的系统评价

中国养老机构老年人群合理用药相关研究的系统评价

中国急性缺血性卒中人群药物经济学研究的系统评价

中西医结合方案治疗脓毒症的Meta分析

他莫昔芬治疗多囊卵巢综合征疗效的系统评价